A randomized, double-blind, placebo-controlled trial of diflunisal on familial amyloid polyneuropathy

A randomized, double-blind, placebo-controlled trial of diflunisal on familial amyloid polyneuropathy - A trial of diflunisal on familial amyloid polyneuropathy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008396

Enrollment

Registered

2012-07-10

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients of familial amyloid polyneuropathy

Interventions

Diflunisal, 500mg / day, PO, 1 year Parse, 500mg / day, PO, 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of familial amyloid polyneuropathy

Exclusion criteria

Exclusion criteria: patients after liver transplantation

Design outcomes

Primary

Measure	Time frame
clinical manifestation	—

Secondary

Measure	Time frame
nerve conduction study data	—

Countries

Japan

Contacts

Public ContactTaro Yamashita

Faculty of Life Sciences, Kumamoto University Department of Neurology

taro-yamashita@fc.kuh.kumamoto-u.ac.jp096-373-5893

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026